Detalles de la búsqueda
1.
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
BMC Cancer
; 20(1): 83, 2020 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-32005111
2.
Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care.
Oncologist
; 24(6): 772-782, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30446581
3.
Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.
Mod Pathol
; 31(6): 947-955, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29410488
4.
Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?
Cancer
; 122(7): 1047-9, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26828851
5.
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
J Thorac Oncol
; 16(4): 601-609, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33388476
6.
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
J Thorac Oncol
; 16(1): 127-139, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33096269
7.
Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
Ann Thorac Surg
; 109(2): 358-366, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31550464
8.
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
J Thorac Oncol
; 15(10): 1611-1623, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32540409
9.
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity.
Genome Biol
; 21(1): 271, 2020 11 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33148332
10.
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
J Thorac Oncol
; 15(9): 1449-1459, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32389639
11.
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Clin Cancer Res
; 26(4): 892-901, 2020 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31694833
12.
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
Clin Lung Cancer
; 20(1): 30-36.e3, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30279110
13.
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
J Thorac Oncol
; 14(6): 1021-1031, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30780001
14.
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
Clin Lung Cancer
; 20(1): 43-47, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30343004
15.
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
Cancers (Basel)
; 11(5)2019 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31137625
16.
Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.
Nat Commun
; 10(1): 552, 2019 01 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30696827
17.
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.
Nat Commun
; 10(1): 2978, 2019 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31278276
18.
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.
Clin Cancer Res
; 24(24): 6195-6203, 2018 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30228210
19.
Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.
Nat Commun
; 9(1): 3114, 2018 08 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30082701
20.
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Nat Med
; 24(5): 638-646, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29686424